Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago.
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.
CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay And thank you for joining Guggenheim during our second SMID Cap conference. I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni.
Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized treatment centers for Casgevy and advancing multiple drug candidates in hemoglobinopathies, CAR-T, and in vivo programs.
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.
DeepSeek AI picks 2 stocks to buy and hold forever
Chinese-based generative artificial intelligence (AI) start-up DeepSeek is dominating conversations in technology and stock markets due to its performance, reportedly rivaling dominant players such as OpenAI's ChatGPT.
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session.
CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last?
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic partnership with Vertex Pharmaceuticals has provided stability and resources, leading to the first FDA-approved CRISPR-based gene editing treatment, Casgevy. Editas' discontinuation of its SCD and TDT program and significant layoffs highlight its precarious position compared to CRISPR's better financial health and strategic advantages.
CRISPR Therapeutics AG (CRSP) 43rd Annual JPMorgan Healthcare Conference - (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) 43rd Annual JPMorgan Healthcare Conference Call January 14, 2025 5:15 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call Participants Fanchen Zhou - JPMorgan Fanchen Zhou Good afternoon, everyone. Thank you for coming here.
